A mouse model for HBV immunotolerance and immunotherapy

Dan Yang, Longchao Liu, Danming Zhu, Hua Peng, Lishan Su, Yang Xin Fu, Liguo Zhang

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Lack of an appropriate small animal model remains a major hurdle for studying the immunotolerance and immunopathogenesis induced by hepatitis B virus (HBV) infection. In this study, we report a mouse model with sustained HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome (AAV/HBV). Similar to the clinical HBV carriers, the mice infected with AAV/HBV were sero-negative for antibodies against HBV surface antigen (HBsAg). Immunization with the conventional HBV vaccine in the presence of aluminum adjuvant failed to elicit an immune response against HBV in these mice. To identify a vaccine that can potentially circumvent this tolerance, the TLR9 agonist CpG was added to HBsAg as an adjuvant. Vaccination of mice with HBsAg/CpG induced not only clearance of viremia, but also strong antibody production and T-cell responses. Furthermore, both the DNA replication and protein expression of HBV were significantly reduced in the livers of AAV/HBV-infected mice. Accordingly, AAV/HBV-infected mice may be used as a robust model for investigating the underlying mechanism(s) of HBV immunotolerance and for developing novel immunotherapies to eradicate HBV infections.

Original languageEnglish (US)
Pages (from-to)71-78
Number of pages8
JournalCellular and Molecular Immunology
Volume11
Issue number1
DOIs
StatePublished - Jan 13 2014

Fingerprint

Hepatitis B virus
Immunotherapy
Dependovirus
Viremia
Virus Diseases
Surface Antigens
Hepatitis B Vaccines
Hepatitis B Surface Antigens
Aluminum
DNA Replication
Antibody Formation
Immunization
Vaccination
Vaccines
Genome
T-Lymphocytes

Keywords

  • AAV vector
  • HBV
  • Immunotherapy
  • Immunotolerance
  • Mouse model

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

A mouse model for HBV immunotolerance and immunotherapy. / Yang, Dan; Liu, Longchao; Zhu, Danming; Peng, Hua; Su, Lishan; Fu, Yang Xin; Zhang, Liguo.

In: Cellular and Molecular Immunology, Vol. 11, No. 1, 13.01.2014, p. 71-78.

Research output: Contribution to journalArticle

Yang, D, Liu, L, Zhu, D, Peng, H, Su, L, Fu, YX & Zhang, L 2014, 'A mouse model for HBV immunotolerance and immunotherapy', Cellular and Molecular Immunology, vol. 11, no. 1, pp. 71-78. https://doi.org/10.1038/cmi.2013.43
Yang, Dan ; Liu, Longchao ; Zhu, Danming ; Peng, Hua ; Su, Lishan ; Fu, Yang Xin ; Zhang, Liguo. / A mouse model for HBV immunotolerance and immunotherapy. In: Cellular and Molecular Immunology. 2014 ; Vol. 11, No. 1. pp. 71-78.
@article{9ef76cd6a0944b8d86d0c51bcd3a41d8,
title = "A mouse model for HBV immunotolerance and immunotherapy",
abstract = "Lack of an appropriate small animal model remains a major hurdle for studying the immunotolerance and immunopathogenesis induced by hepatitis B virus (HBV) infection. In this study, we report a mouse model with sustained HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome (AAV/HBV). Similar to the clinical HBV carriers, the mice infected with AAV/HBV were sero-negative for antibodies against HBV surface antigen (HBsAg). Immunization with the conventional HBV vaccine in the presence of aluminum adjuvant failed to elicit an immune response against HBV in these mice. To identify a vaccine that can potentially circumvent this tolerance, the TLR9 agonist CpG was added to HBsAg as an adjuvant. Vaccination of mice with HBsAg/CpG induced not only clearance of viremia, but also strong antibody production and T-cell responses. Furthermore, both the DNA replication and protein expression of HBV were significantly reduced in the livers of AAV/HBV-infected mice. Accordingly, AAV/HBV-infected mice may be used as a robust model for investigating the underlying mechanism(s) of HBV immunotolerance and for developing novel immunotherapies to eradicate HBV infections.",
keywords = "AAV vector, HBV, Immunotherapy, Immunotolerance, Mouse model",
author = "Dan Yang and Longchao Liu and Danming Zhu and Hua Peng and Lishan Su and Fu, {Yang Xin} and Liguo Zhang",
year = "2014",
month = "1",
day = "13",
doi = "10.1038/cmi.2013.43",
language = "English (US)",
volume = "11",
pages = "71--78",
journal = "Cellular and Molecular Immunology",
issn = "1672-7681",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A mouse model for HBV immunotolerance and immunotherapy

AU - Yang, Dan

AU - Liu, Longchao

AU - Zhu, Danming

AU - Peng, Hua

AU - Su, Lishan

AU - Fu, Yang Xin

AU - Zhang, Liguo

PY - 2014/1/13

Y1 - 2014/1/13

N2 - Lack of an appropriate small animal model remains a major hurdle for studying the immunotolerance and immunopathogenesis induced by hepatitis B virus (HBV) infection. In this study, we report a mouse model with sustained HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome (AAV/HBV). Similar to the clinical HBV carriers, the mice infected with AAV/HBV were sero-negative for antibodies against HBV surface antigen (HBsAg). Immunization with the conventional HBV vaccine in the presence of aluminum adjuvant failed to elicit an immune response against HBV in these mice. To identify a vaccine that can potentially circumvent this tolerance, the TLR9 agonist CpG was added to HBsAg as an adjuvant. Vaccination of mice with HBsAg/CpG induced not only clearance of viremia, but also strong antibody production and T-cell responses. Furthermore, both the DNA replication and protein expression of HBV were significantly reduced in the livers of AAV/HBV-infected mice. Accordingly, AAV/HBV-infected mice may be used as a robust model for investigating the underlying mechanism(s) of HBV immunotolerance and for developing novel immunotherapies to eradicate HBV infections.

AB - Lack of an appropriate small animal model remains a major hurdle for studying the immunotolerance and immunopathogenesis induced by hepatitis B virus (HBV) infection. In this study, we report a mouse model with sustained HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome (AAV/HBV). Similar to the clinical HBV carriers, the mice infected with AAV/HBV were sero-negative for antibodies against HBV surface antigen (HBsAg). Immunization with the conventional HBV vaccine in the presence of aluminum adjuvant failed to elicit an immune response against HBV in these mice. To identify a vaccine that can potentially circumvent this tolerance, the TLR9 agonist CpG was added to HBsAg as an adjuvant. Vaccination of mice with HBsAg/CpG induced not only clearance of viremia, but also strong antibody production and T-cell responses. Furthermore, both the DNA replication and protein expression of HBV were significantly reduced in the livers of AAV/HBV-infected mice. Accordingly, AAV/HBV-infected mice may be used as a robust model for investigating the underlying mechanism(s) of HBV immunotolerance and for developing novel immunotherapies to eradicate HBV infections.

KW - AAV vector

KW - HBV

KW - Immunotherapy

KW - Immunotolerance

KW - Mouse model

UR - http://www.scopus.com/inward/record.url?scp=84891757964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891757964&partnerID=8YFLogxK

U2 - 10.1038/cmi.2013.43

DO - 10.1038/cmi.2013.43

M3 - Article

VL - 11

SP - 71

EP - 78

JO - Cellular and Molecular Immunology

JF - Cellular and Molecular Immunology

SN - 1672-7681

IS - 1

ER -